$TFX

Teleflex Inc. (NYSE: TFX) will showcase its Dynetic-35 Stent System at CIRSE 2026. The system, supported by the BIONETIC-TRA study, demonstrated 100% procedural success for treating iliac artery lesions via trans-radial approach, offering an alternative to traditional femoral access. The study, led by Dr. Michael Lichtenberg, showed low radial artery occlusion rates and a non-complex learning curve.

Analysts updated price targets and ratings for several companies. UBS raised Fluence Energy's target to $12, Morgan Stanley increased Dynatrace's to $65, and Raymond James boosted Nvidia's to $352. Other companies include Snowflake, Teleflex, Coinbase, Expedia, Micron, AMD, and SanDisk, with varying target changes and ratings.

Teleflex Inc. completed the sale of its OEM business to Montagu and Kohlberg for $1.5B. The divestiture aligns with its strategy to focus on core businesses and return capital to shareholders. Teleflex plans to use proceeds for debt reduction and share repurchases, aiming to enhance financial flexibility and growth.

A specialty-stocks earnings recap compares Q2 results for LeMaitre (LMAT), Teleflex (TFX), Integra LifeSciences (IART), and Intuitive Surgical (ISRG). The group’s revenues beat consensus by 0.8%, but next-quarter guidance was 1.6% below. LMAT revenue was $70.38M (+9.6%) but missed by 1.7% and EPS. TFX revenue was $570.3M (+28.9%) beat by 2%. IART revenue $418.8M flat, in line. ISRG revenue $2.89B (+18.5%) beat by 2.6%.

Teleflex (TFX) Q2 2026 earnings call said pro forma adjusted constant-currency growth was 4.7%, adjusted operating margin 19.6%, and it delivered better-than-expected revenue, margin, and adjusted EPS. Interventional growth lagged due to slower VI acquisition integration. Teleflex closed the OEM divestiture, raising about $1.5B after-tax proceeds $1.25B, and expects Acute Care and Interventional Urology divestiture completion in Q4 2026 pending FTC review.

Teleflex (NYSE:TFX) said non product-related disruption during BIOTRONIK Vascular Intervention integration affected the acquired revenue base. It now expects full integration through 2H26. Teleflex completed its OEM sale, raising about $1.5B proceeds, and repurchased 1.9M shares for $250M. 2026 pro forma revenue growth guidance was cut to 3.5% to 4.5%, while adjusted EPS was raised to $6.90 to $7.20.

Teleflex (NYSE:TFX) reported Q2 CY2026 results. Revenue rose 28.9% year on year to $570.3 million, topping Wall Street estimates by 2%, according to the company. Non-GAAP adjusted EPS was $1.76, 37.4% above analysts’ consensus. The article also cites full-year EPS expectations of $8.86 versus $8.75.

TELEFLEX INC (TFX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FOR IMMEDIATE RELEASE August 6, 2026 Teleflex Reports Second Quarter Finan cial Results and Full Year 2026 Outlook Completes Sale of OEM Business and Will Deploy Net Proceeds to Reduce Debt and Repurchase Common Stock Announces $250 Million Accelerated Share Repurcha

Teleflex (NYSE: TFX) is set to report Q2 earnings Thursday. The article notes last quarter’s revenue of $548.3 million, up 32.3% year on year, with EPS beating but full-year EPS guidance missing. Consensus expects Q2 revenue up 26.4% year on year. Analysts’ estimates were largely unchanged; the average price target is $149.45 versus $141.68.

TELEFLEX INC (TFX) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Teleflex Completes Strategic Divestiture of OEM Business for $1.5 Billion Intends To Utilize Net Proceeds To Pay Down Debt and Repurchase Shares Wayne, Pa., August 3, 2026 - Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today an